Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 4/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | CFTR | P13569 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10262462 | 1.00 | PRKDC (0.34) | PRKDCAKT1PIK3CDPIK3CAMEN1 | |
| SCHEMBL13868646 | 0.96 | PRKDC (0.36) | PRKDCAKT1PIK3CDPIK3CAMEN1 | |
| SCHEMBL15449577 | 0.93 | PRKDC (0.34) | PRKDCAKT1PIK3CDPIK3CAMEN1 | |
| SCHEMBL10262395 | 0.93 | PRKDC (0.34) | PRKDCAKT1PIK3CDPIK3CAMEN1 | |
| SCHEMBL13868628 | 0.93 | PRKDC (0.34) | PRKDCAKT1PIK3CDPIK3CAMEN1 | |
| SCHEMBL10292860 | 0.93 | PRKDC (0.34) | PRKDCAKT1PIK3CDPIK3CAMEN1 | |
| SCHEMBL10267980 | 0.93 | PRKDC (0.34) | PRKDCAKT1PIK3CDPIK3CAMEN1 | |
| SCHEMBL13868685 | 0.93 | PRKDC (0.34) | PRKDCAKT1PIK3CDPIK3CAMEN1 | |
| SCHEMBL13868695 | 0.93 | ITK (0.34) | PRKDCAKT1 | |
| SCHEMBL13868686 | 0.93 | PRKDC (0.34) | PRKDCAKT1PIK3CDPIK3CAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521004-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2009-04-21 | — | — | US | disclosed |
| US-7521004-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1674460-B1 | CHROMENE COMPOUND | TOKUYAMA CORP (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20070215844-A1 | Chromene Compound | TOKUYAMA CORPORATION (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070215844-A1 | Chromene Compound | TOKUYAMA CORPORATION (JP) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070215844-A1 | Chromene Compound | CRY2, TYR, CRY1 | PRKDC 3723/4885AKT1 3833/4885PIK3CD 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.